

## Regimen Reference Order – BRST – T-DM1 (Kadcyla®) Metastatic

ARIA: BRST – [T-DM1 (Kadcyla) METASTATIC]

Planned Course: Every 3 weeks until disease progression or unacceptable toxicities

Indication for Use: Breast Cancer Metastatic or Locally Advanced

CVAD: At Provider's Discretion

**Proceed with treatment if:**

**ANC equal to or greater than  $1.5 \times 10^9/L$  AND Platelets equal to or greater than  $50 \times 10^9/L$**

❖ Contact Physician if parameters not met

### SEQUENCE OF MEDICATION ADMINISTRATION

#### Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

#### Treatment Regimen – BRST – T-DM1 (Kadcyla®) Metastatic

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
<b>Cycle 1 Only</b>		
dexamethasone	8 mg	Orally 30 minutes pre-chemotherapy
T-DM1 (Kadcyla®)	3.6 mg/kg	IV in normal saline 250 mL over 90 minutes Use 0.2 or 0.22 micron filter <i>*Alert: Ensure that T-DM1 (brand name Kadcyla®) is dispensed and administered</i>
<b>Cycle 2 and Onwards</b>		
dexamethasone	8 mg	Orally 30 minutes pre-chemotherapy
T-DM1 (Kadcyla®)	3.6 mg/kg	IV in normal saline 250 mL over 30 minutes Use 0.2 or 0.22 micron filter <i>*Alert: Ensure that T-DM1 (brand name Kadcyla®) is dispensed and administered</i>
All doses will be automatically rounded that fall within the DSG Approved Dose Bands. See BRST DSG – Dose Banding document for more information		

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

## REQUIRED MONITORING

### All Cycles

- CBC and biochemistry as per Physician Orders

### Cardiac Monitoring

- Left Ventricular Ejection Fraction (LVEF) monitoring is recommended at baseline and every 4 cycles for the first 2 years then every 4 to 8 cycles thereafter

### Cycle 1 Only

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O<sub>2</sub> saturation) at baseline and as clinically indicated
- Observe patient for 90 minutes after administration
- Full vital signs prior to discharge

### Cycle 2 and Onwards

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O<sub>2</sub> saturation) at baseline and as clinically indicated
- Observe patient for 30 minutes after administration of Cycles 2 and 3 only
- Full vital signs prior to discharge

## Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

## DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

## ADDITIONAL INFORMATION

- T-DM1 (Kadcyla®) is also called trastuzumab emtansine
- There is a risk of medication errors between T-DM1 (Kadcyla®) and trastuzumab. In order to minimize the risk, check the regimen ordered, the vial labels, and the prescription label to ensure that the drug being prepared and administered is T-DM1 (Kadcyla®)